

SUBJECT INDEX

- Abdominal compartment syndrome, in extracorporeal membrane oxygenation, 890–892
- Activated coagulation time, factors affecting, 563–568
- Acute respiratory distress syndrome
extracorporeal membrane oxygenation for, beta blockers with, 58–63
prone ventilation for, 471–475
surfactant for, 849–856, e50
- Air embolism
in brain, in lung transplantation, 1077–1079
in cardiopulmonary bypass, 468–470
- Airway management
difficult extubation in, 1067–1068
in pulmonary hypertension, 940–944
retromolar tube placement for, e44–e46
- Algorithms, 759–761
- Aminocaproic acid, for blood conservation, 5, 123
- Amiodarone, hepatotoxicity of, 729–732
- AMPLATZER occluding devices, 135–136
- Anaphylaxis, due to factor VIIa, e15–e17
- Anemia, kidney injury due to, 690
- Aneurysm
aortic
 B-type natriuretic peptide levels in, 637–642
 cerebral ischemia in, e62–e63
 repair of
 atheroembolism in, e5–e6
 cardiac output measurement in, 223–226
 factor VIIa reaction in, e15–e17
 fibrinogen concentrate for, 654–659, e54–e56
 innovations in, 959–965
 myocardial performance index during, 204–208
 pulmonary artery, with associated anomalies, 280–282
 sinus of Valsalva, misdiagnosis of, 349–351
- Angiotensin blockers, for aortic dissection, 1140
- Angiotensin-converting enzyme inhibitors, kidney injury due to, 688–690
- Animal studies
lung re-expansion after one-lung ventilation, 427–432
myocardial protection, 403–406
spinal cord ischemia protection, 1034–1038
- Annular height-to-commissural width ratio, mitral valve, 186–190
- Antibiotics
kidney injury due to, 694
prophylactic, 1096–1097
- Anticoagulants, 2340–2341
for extracorporeal membrane oxygenation, 906
new, 736–739
oral factor Xa inhibitors, 4
- Antifibrinolytics
for blood conservation, 5
for cardiopulmonary bypass, 671–674
decisions for, rotational thromboelastometry for, 1089
- Antiplatelet agents, perioperative management of, 680–686
- Aorta
aneurysm of. *See* Aneurysm, aortic
coarctation of, repair of, 139
cross-clamping of
 cardiac output measurement in, 223–226
 myocardial performance index during, 204–208
dissection of
 after CABG, e11–e12
 during cardioplegic cannula insertion, e3–e5
 complications of, 1139–1144
- Aorta (*Continued*)
dynamic true lumen collapse in, 970–972
with hemophilia, 660–663
repair of, hiatal hernia exacerbation after, e41–e42
occlusion of, 462–464
thrombosis in, bowel ischemia in, e13–e15
- Aortic arch, injury of, in central venous catheter insertion, 101–103
- Aortic root, dynamic true lumen collapse in, 970–972
- Aortic valve
bicuspid, repair of, 928
bypass for, 148–160
fusion of, after left ventricular assist device support, 1060–1062
insufficiency of, mitral regurgitation with, 1153–1155
regurgitation of
 after left ventricular assist device implantation, 1063–1066
 repair or replacement for, 923–932
 tiling-disc mitral valve with, 966–967
repair of
 for aortic insufficiency, 923–932
 CABG with, 232–238
 for insufficiency, 923–932
replacement of. *See also* Transcatheter procedures, aortic valve implantation
 B-type natriuretic peptide in, 624–630
 diastolic mitral regurgitation and, 283–285
 incidentally detected patent foramen ovale in, 721–728
 for insufficiency, 923–932
 probrain natriuretic peptide vs. echocardiographic evaluation before, 197–203
 survival prediction in, 617–623
 transesophageal echocardiography for, 95–97, 688–710
stenosis of, bypass surgery for, 148–160
surgery on
 LUCAS-2 device and, e50–e51
 mitral valve injury during, 748–750
 unicuspid, echocardiography for, 277–279
- Aorto-atrial fistula, echocardiography for, e76–e78
- Apicoaortic conduit surgery, 148–160
- Apixaban, 4, 742–743
- Apps, for anesthesia, 322–326
- Aprotinin
increased mortality due to, 764–772
kidney injury due to, 692
- Arrhythmias
after CABG, magnesium for, 643–650
in pulmonary artery catheterization, position impact on, 391–394
- Aspirin
after CABG, 575–580
for kidney injury prevention, 688
perioperative management of, 680–685, e35–e36
resistance to, after CABG, e46–e47
- Atheroembolism, in aortic aneurysm repair, e5–e6
- Atrial fibrillation
after CABG, 729–732
apixaban for, 742–743
electrical cardioversion for, 799–803
factor Xa inhibitors for, 4
in pneumothorax, e43–e44
pulmonary vein isolation for, 433–438
rivaroxaban for, 741
- Atrial flutter, during hemodialysis, 535–536
- Atrial septal defect
with anomalous right upper pulmonary venous return, 975–977
closure/repair of, 134–135, 537–539

- Atrial septal defect (*Continued*)
 with associated pulmonary artery anomalies, 280–282
 early extubation after, 773–775
 mediastinal drain damage in, 104–105
 pneumothorax after, e43–e44
 totally thoracoscopic surgery for, 270–273
 echocardiographic techniques for, e79–e80
 ridge-shaped, 346–348
- Atrioventricular delay, in biventricular pacing, 209–216
- Atrioventricular septal defect, repair of, 973–974
- Atrium
 left
 ridge in, 346–348
 thrombi in, incidental discovery of, 354–355
 mass in, in CABG redo, 1148–1149
 myxoma of, removal of, totally thoracoscopic surgery for, 270–273
 right, lymphoma of, 172–174
 thrombus in, during extracorporeal membrane oxygenation, e12–e13
- Autologous blood, use of, 121–122
- Automation
 future of, 718
 of isovelocity surface area measurement, 507–511
- Autoregulation, of cerebral blood flow, after left ventricular assist device implantation, 1022–1028
- Bariatric surgery, with implanted left ventricular assist device, 880–882
- Beta blockers, 2090–2094
 for aortic dissection, 1140
 with extracorporeal membrane ox, 58–63
 in general anesthesia, heart rate reduction in, 414–419
 pharmacogenomics of, 1101–1107
 for post-traumatic stress disorder, 265–269
 preoperative noncompliance with, 1029–1033
- Bicuspid aortic valve
 fusion of, in left ventricular assist device support, 1060–1062
 repair of, 928
- Biomarkers
 for aortic aneurysm, 959–960
 for kidney injury, 340–345
- Bispectral index, in mitral regurgitation, anesthesia depth and, 994–998
- Biventricular pacemakers, optimization of, 209–216
- Black denaturalization, of oral mucosa, in transesophageal echocardiography, e18–e19
- Bland-Altman analysis, for cerebral oximetry validation, 1007–1014
- Bland-White-Garland syndrome, 286–290
- Bleeding and blood loss. *See also* Blood conservation; Transfusions
 aspirin discontinuation and, 245–250
 in CABG, surgeon impact on, 550–556
 decreasing, 122–125
 in extracorporeal membrane oxygenation, 906
 with intra-aortic balloon pump, 604–607
 postoperative, outcome and, 46–51
 prevention of, e68–e70
 rotational thromboelastometry in, 1083–1093
- Blood conservation, 4–6
 for CABG, 545–549
 in factor VII deficiency, 651–653
 updates on, 117–133, e75
- Blood transfusions. *See* Transfusions
- Blue Phantom echocardiography simulator, 482
- Body mass index
 CABG mortality and, 813–817
 early extubation and, 773–775
- Bowel ischemia, in aortic thrombosis, e13–e15
- Brachiocephalic trunk, aberrant, tracheostomy with, e72–e73
- Brachiocephalic vein, bullet migration from, 459–461
- Brain. *See also subjects starting with* Cerebral
 air embolism in, in lung transplantation, 1077–1079
 blood flow in, after left ventricular assist device implantation, 1022–1028
 disorders of
 in CABG, volatile anesthetics effects on, 395–402
 jugular venous pressure effects on, 999–1006
 oximetry for, accuracy of, 1007–1014
 protection of, in deep hypothermic cardiac arrest, 333–339
- Brain natriuretic peptide, as aortic aneurysm biomarker, 960
- Bronchoscopy, extracorporeal membrane oxygenation for, 465–467
- B-type natriuretic peptide, prognostic value of
 for aortic surgery, 637–642
 for cardiac surgery, 624–630, e6
- Bullet embolism, in right ventricle, 459–461
- Bupivacaine
 for lung surgery, 863–867
 for thoracotomy pain, 83–89
- CABG surgery. *See* Coronary artery bypass graft (CABG) surgery
- Calcification, mitral valve, 327–333
- Cangrelor, perioperative management of, 683
- Carcinoid crisis, vasoplegic syndrome in, methylene blue for, 878–879
- Carcinoma, renal cell, embolization during nephrectomy, 1069–1073
- Cardiac arrest, in drowning, extracorporeal membrane oxygenation implantation for, 887–889
- Cardiac catheterization, 134–137
- Cardiac index, measurement methods for, 217–222
- Cardiac output
 measurement methods for, 223–226
 monitoring of, in off-pump CABG surgery, 1131–1135, 1136–1138
- Cardiac surgery. *See also specific procedures*
 algorithms for, 759–761
 infectious complications of, 1094–1100
 jugular venous pressure in, brain injury and, 999–1006
 noninvasive ventilation after, 917–919
 rotational thromboelastometry in, 1083–1093
- Cardiac tamponade, after cardiac surgery, 302–311
- Cardiomyopathy
 postpartum, left ventricular assist device for, 1060–1062
 stress-induced, after foramen ovale closure, e52–e54
- Cardioprotection. *See* Myocardial protection
- Cardiopulmonary bypass
 air embolism in, 468–470
 biocompatible, 557–562
 blood conservation in, 117–133, e75
 chest tube drainage in, e68–e70
 coagulopathy management in, 669–679
 diabetic ketoacidosis in, 910–916
 hemostasis interventions in, thromboelastometry effects on, 227–231
 heparin resistance in, nafamostat mesilate for, 239–244
 heparin-induced hyperkalemia in, 106–109
 hypothermia vs. warm conditions for, 945–951
 intraventricular vortex ring formation inhibition in, 376–380
 kidney dysfunction or failure after, 64–69, 691–693, 1080–1082, e19–e20
 levosimendan for, 596–603
 lung protection during, 448–454
 neuraxial anesthesia for, heparin administration and, 581–584
 outcomes of, vs. duration, e18
 pacing optimization after, 291–301
 post-traumatic stress disorder after, 265–269
 renal blood flow measurement during, 39–45

- Cardiopulmonary bypass (*Continued*)
 renal cell tumor thrombus during, 1124–1130
 separation from, difficult and complex, 608–616
 steroid prophylaxis for, 952–958
 sublingual microcirculation during, 785–790
 for thoracoscopic surgery, 270–273
- Cardioversion, for atrial fibrillation, 799–803
- Carotid artery(ies)
 avoidance of, in internal jugular vein cannulation, 979–981, 982–984, 985–988
 disease of, recent advances in, 166–171
 stenosis of, treatment comparisons for, 835–844
- Caseous calcification, mitral valve, 327–333
- Catheter(s)
 central venous. *See* Central venous catheter
 procedures using. *See* Transcatheter procedures
 pulmonary artery, adjacent to papillary muscle, 175–177
 urinary, infections in, 1095–1096
 vascular, infections in, 1095–1096
- Catheter ablations, 140–141
- Catheterization
 cardiac, 134–137
 pulmonary artery, arrhythmias during, position impact on, 391–394
- Cell phones, anesthesia apps for, 322–326
- Central venous catheter
 infections in, 1095–1096
 placement of
 arterial injury due to, 101–103
 with subcutaneous emphysema, e46
 ultrasound-guided, 979–981, 982–984, 985–988
- Central venous oxygen saturation, as marker for occult hypoperfusion, 52–57
- Cerebral blood flow, after left ventricular assist device implantation, 1022–1028
- Cerebral ischemia, in superior vena cava obstruction, near-infrared spectroscopy for, e27–e28, e62–e63
- Cerebral oximetry
 accuracy of, 1007–1014
 for outcome prediction, 1015–1021
- Chest compression, as bridge to aortic valve surgery, e50–e51
- Chest pain
 refractory, thoracic epidural analgesia effects on, 822–828
 in sternal fracture, 532–534
- Chest tube drainage
 as outcome measure, 46–51
 prevention of, e68–e70
- Children. *See* Pediatric patients
- Chlorhexidine oral rinse, for mortality reduction, 764–772
- Circumflex artery injury, in mitral valve repair, 512–519
- Clevidipine, for pheochromocytoma surgery, 527–528
- Clonidine
 for kidney injury prevention, 688
 for mortality reduction, 764–772
- Clopidogrel
 discontinuation of, 4–5
 perioperative management of, 685–686
- Closed-loop fluid administration system, 933–939
- Coagulation
 activation of, in cardiopulmonary bypass, reduction of, 557–562
 monitoring of, rotational thromboelastometry in, 1083–1093
- Coagulation factors, for blood conservation, 123–124
- Coagulopathy, management of, in cardiac surgery, 669–679
- Cognitive dysfunction, in cardiac surgery, jugular venous pressure and, 999–1006
- Compartment syndrome
 abdominal, in extracorporeal membrane oxygenation, 890–892
 in aortic occlusion, 462–464
- Compliance, with perioperative beta-blocker therapy, 1029–1033
- Computed tomography
 for coronary artery fistula, e58–e60
 for saphenous vein graft pseudoaneurysm, 1148–1149
- Computers
 algorithms and, 759–761
 anesthesia apps for, 322–326
- Confusion, postoperative, e23–e24
- Congenital heart disease. *See also specific defects*
 dizziness in, 975–977
 pacing in, 299
 surgery for, 141
 acute respiratory distress syndrome after, 471–475
 in adults, early extubation for, 773–775
 air embolism in, 468–470
 mediastinal drain damage in, 104–105
 neuraxial anesthesia for, heparin administration and, 581–584
 renal blood flow measurement in, 39–45
- Continuous positive airway pressure, for respiratory failure, after cardiac surgery, 448–454
- Contrast agents, kidney injury due to, 688–689, 804–812
- Cor triatriatum, incomplete, 346–348
- Cor triatriatum dexter, atrial septal defect with, 537–539
- Coronary artery(ies)
 anomalous, rising from pulmonary artery, 286–290, e70–e72
 fistula of, ligation of, e58–e60
 spasms of, e78–e79
- Coronary artery bypass graft (CABG) surgery
 amiodarone hepatotoxicity after, 729–732
 aortic valve repair with, tranexamic acid usage in, 232–238
 arrhythmias after, magnesium for, 643–650
 aspirin action after, 575–580
 aspirin discontinuation before, 245–250, e35–e36
 aspirin resistance after, e46–e47
 bleeding exploration after, 550–556
 B-type natriuretic peptide in, 624–630
 carotid artery disease with, 166–171
 cerebral blood flow autoregulation after, 1022–1028
 cerebral oximetry measurement in, 1015–1021
 chest tube drainage after, 46–51
 Cuirass ventilation after, 873–877
 echocardiography techniques in, 17–25
 erythropoietin concentrations impact on, 251–257
 with factor V Leiden mutation and thromboangiitis obliterans, e42–e43
 failure of, 371–375
 fluid responsiveness after, pulse pressure variation and, 387–390
 gabapentin after, e26
 in heart failure, 7–8
 hemostasis interventions in, thromboelastometry effects on, 227–231
 heparin resistance in, nafamostat mesilate effects on, 239–244
 heparin-induced hyperkalemia in, 106–109
 intrathoracic fire during, 520–521
 intraventricular vortex ring formation inhibition in, 376–380
 kidney function after, 591–595, 804–812
 levosimendan for, 591–595, 596–603
 morbidity in, body mass index and, 813–817
 N-terminal pro-brain natriuretic peptide after, 631–636
 occult hypoperfusion markers in, 52–57
 off-pump
 aortic dissection after, e11–e12
 continuous cardiac output monitoring in, 1131–1135, 1136–1138

- Coronary artery bypass graft (CABG) surgery (*Continued*)
 hypoxemia in, e38–e39
 spectral entropy monitoring for, 818–821
 outcomes of, EuroSCORE predictions for, 258–264
 post-traumatic stress disorder after, 265–269
 probrain natriuretic peptide vs. echocardiographic evaluation before, 197–203
 redo, saphenous vein graft pseudoaneurysm in, 1148–1149
 regional wall motion during, 371–375
 respiratory failure after, noninvasive ventilation for, 443–447, e73–e75
 segmental wall motion abnormalities and, 191–196
 survival prediction in, 617–623
 transfusion reduction for, 545–549
 vasospasm in, e78–e79
 volatile anesthetics for, 395–402, 791–798
- Coronary artery disease, advances in, 7–8
- Coronary ostium, right, funnel-shaped, 352–353
- Coronary sinus, obstruction of, 1074–1078
- Corticosteroids, for cardiopulmonary bypass, 952–958
- Creatinine, in kidney injury, 341
- Cuirass ventilation, after cardiac surgery, 873–877
- Cystatin C, in kidney injury, 342
- Cytochrome P450 enzymes, pharmacogenomics variations in, 1102–1103, 1107–1109
- Cytokines, after one-lung ventilation re-expansion, 427–432
- Dabigatran, 4
- D-dimer, as aortic aneurysm biomarker, 959–960
- Deep hypothermic cardiac arrest, topical hypothermia with, 333–339
- Defibrillators, implantation of, 139–140
- Delirium, postoperative, e23–e24
- Denmark, EuroSCOREs for, 258–264
- Desflurane, for CABG, 791–798
- Desmopressin, in cardiopulmonary bypass, 676
- Device infections, 1095–1096
- Dexamethasone, for cardiopulmonary bypass, 952–958
- Dexmedetomidine, for interventional cardiology, 142–143
- Diabetes mellitus, kidney injury and, 692
- Diabetic ketoacidosis, in cardiopulmonary bypass, 910–916
- Dialysis, superior vena cava syndrome in, 1150–1152
- Diaphragmatic hernia, chest mass in, 1156–1158
- Diastolic function
 assessment of, 1115–1123
 probrain natriuretic peptide vs. echocardiographic results, 197–203
- Digestive tract, selective decontamination of, for mortality reduction, 764–772
- Dissection, aortic. *See* Aorta, dissection of
- Dizziness
 in adult congenital heart disease, 975–977
 in right atrial lymphoma, 172–174
- Dobutamine stress test, segmental wall motion abnormalities and, 191–196
- Doppler studies, for diastolic dysfunction, 1115–1123
- Dressing, for blood conservation, 124–125
- Drowning, extracorporeal membrane oxygenation implantation for, 887–889
- Drug abuse, sternal fracture in, 532–534
- Ductus arteriosus, ligation of, e39–e41
- Dyspnea, in dialysis, 1150–1152
- Echocardiography
 color M-mode, for patent foramen ovale, e67–e68
 for diastolic dysfunction, 1115–1123
 vs. probrain natriuretic peptide, for preoperative evaluation, 197–203
 simulation in, 476–485
- Echocardiography (*Continued*)
 transesophageal. *See* Transesophageal echocardiography
 transthoracic. *See* Transthoracic echocardiography
- EchoCom echocardiography simulator, 478–479
- Edema, pulmonary, from nasogastric tube, e37–e38
- Editorials
 Algorithms: What Computers Do Best, 759–761
 Emergent Echocardiography in Noncardiac Surgical Patients, 359–361
 Going With the Flow: The Dilemma of a Laminar Jet, 525
 Hands-on . . . Handoff, 1–2
 High Transvalvular Gradients Across a Prosthetic Valve in the Mitral Position: Not Ignoring the Bigger Picture, 968–969
 Landmark-Guided Internal Jugular Vein Cannulation: Is There Still a Role and, If So, What should We Do About It?, 979–981
 Mea Culpa: Scientific Misconduct, 181–185
 Surgical Management of Ischemic Mitral Valve Regurgitation: Rerelearning Our Lessons, 756–757
 Transesophageal Echocardiography and Noncardiac Surgery: How Far Does the Nondiagnostic Use Go?, 356–357
 Variability in Transfusion Practice and Effectiveness of Strategies to Improve It, 541–544
 Web-Enabled Democracy-Based Consensus in Perioperative Medicine: Sedition or Solution?, 762–763
- Education
 for closed-loop system, 933–939
 for echocardiography, 476–485
- Edwards SAPIEN device, 137
- Elderly persons
 CABG in, fluid responsiveness after, 387–390
 high thoracic epidural analgesia for, 1039–1047, 1048–1054
 tranexamic acid use in, 232–238
- Electrophysiology procedures, 140–141
 biventricular pacing, 209–216
 cardioversion, for atrial fibrillation, 799–803
 pulmonary vein isolation, 433–438
- Elinogrel, perioperative management of, 684
- Embolism
 air
 in brain, in lung transplantation, 1077–1079
 in cardiopulmonary bypass, 468–470
 athero-, in aortic aneurysm repair, e5–e6
- Emergency
 airway management in, 940–944
 transesophageal echocardiography in, 359–361, 362–370
- Emphysema, subcutaneous, central venous cannulation with, e46
- Endarterectomy, carotid
 vs. medical therapy or combined therapy, 835–844
 recent advances in, 166–171
- Endotracheal bioimpedance cardiography, vs. transpulmonary thermidulation, 217–222
- Endotracheal extubation
 for congenital heart disease surgery, in adults, 773–775
 difficult, case examples of, 1067–1068
- Endotracheal intubation
 laryngoscopic techniques for, 845–848
 nasogastric tube interferences with, e37–e38
- Endovascular techniques, for aortic aneurysm, 961–963
- Epicardial echocardiography, vs. transesophageal echocardiography, 32–38
- Epidural anesthesia or analgesia
 high thoracic, for cardiac surgery, 1039–1047, 1048–1054

- Epidural anesthesia or analgesia (*Continued*)
 magnesium in, 1055–1059
 for thoracotomy, 78–82, 83–89, 666–668
 for video-assisted thoracoscopic surgery, 313–314
- Equanox Cerebral Oximetry System, accuracy of, 1007–1014
- Errata, Carmona, April 1012 issue, 758
- Erythropoietin
 for blood conservation, 5, 121, 651–653
 cardioprotective effects of, 251–257
- Esmolol
 with extracorporeal membrane ox, 58–63
 in general anesthesia, heart rate reduction in, 414–419
- Esophageal resection
 anesthesia comparisons for, 857–862
 postoperative infections in, 569–574
- Ethical issues, 181–185
- EuroSCORE
 in Danish population, 258–264
 survival predictions with, after aortic valve replacement, 617–623
- EVEREST II study, 6
- Evidence-based medicine
 magic bullets in, 455–458
 vs. practice, 715–716
- Extracorporeal membrane oxygenation
 abdominal compartment syndrome in, 890–892
 for bronchoscopy, 465–467
 cardiac thrombosis in, 664–665
 for cardiogenic shock, 161–165
 implantation by median sternotomy, 887–889
 intracardiac clot formation in, e12–e13
 jugular venous pressure in, brain injury and, 999–1006
 for respiratory failure, beta blockers with, 58–63
 retained fibrin sleeve from, 883–886
 for right ventricular laceration, 98–100
 venovenous, 893–909
- Extubation
 for congenital heart disease surgery, in adults, 773–775
 difficult, 1067–1068
- EZ Double-Balloon Blocker, for one-lung ventilation, e35
- Factor concentrates, for blood conservation, 5
- Factor V Leiden mutation, CABG with, e42–e43
- Factor VII deficiency, cardiac surgery in, blood conservation for, 651–653
- Factor VIIa
 activated, decisions for, rotational thromboelastometry for, 1088–1089
 for aortic aneurysm repair, anaphylactic reaction to, e15–e17
 usage of, thromboelastometry effects on, 227–231
- Factor VIII concentrate, aortic dissection repair with, 660–663
- Factor Xa inhibitors, 4, 740–745
- Factor XIII, in cardiopulmonary bypass, 675–676
- Fenoldopam, in kidney failure prevention, 407–413, 688
- Fibrin sealants, e75
- Fibrin sleeve, from extracorporeal membrane oxygenation equipment, 883–886
- Fibrinogen, as aortic aneurysm biomarker, 959–960
- Fibrinogen concentrate, as fresh frozen plasma alternative, 654–659, e54–e56
- Fibrinogen-rich components, decisions for, rotational thromboelastometry for, 1087–1088
- Fibrinolysis, activation of, in cardiopulmonary bypass, reduction of, 557–562
- Fires, in operating room, during CABG, 520–521
- Fistula
 aorto-atrial fistula, echocardiography for, e76–e78
 coronary artery, ligation of, e58–e60
- Fluid responsiveness, after CABG, pulse pressure variation and, 387–390
- Fluid therapy
 for aortic aneurysm, 961
 closed-loop fluid administration system for, 933–939
 kidney function and, 690–691, 693
- Focused transthoracic echocardiography, for perioperative mortality prediction, 989–993
- Foramen of Morgagni, omental hernia through, 1156–1158
- Foramen ovale, patent
 in CABG, hypoxemia in, e38–e39
 closure of, stress-induced cardiopathy after, e52–e54
 color M-mode echocardiography for, e67–e68
 incidental detection of, 721–728
- Fresh frozen plasma, 5
 alternatives to, 654–659, e54–e56
- Furosemide, kidney injury due to, 693
- G protein signaling system, genetic polymorphisms of, 1106, 1110
- Gabapentin, for postoperative pain, e26
- Gastric bypass, with implanted left ventricular assist device, 800–882
- Gastric tube insertion, pediatric airway scope for, e52
- General anesthesia
 nasogastric tube complications in, e37–e38
 vs. sedation, for interventional cardiology, 141–142
 for transcatheter aortic valve implantation, 733–739
 for vascular surgery, preoperative beta blockers in, 414–419
- Glial fibrillary acidic protein
 in CABG, volatile anesthetics effects on, 395–402
 in cardiac surgery, jugular venous pressure and, 999–1006
- Glucose
 for CABG, N-terminal pro-brain natriuretic peptide and, 631–636
 control of, for infection prevention, 1097–1098
- Glycemic control, for mortality reduction, 764–772
- GPIIb inhibitors, perioperative management of, 683
- Gunshot wounds, of right ventricle, 459–461
- Halo traction device, for subclavian vein cannulation, e56–e58
- Handoff protocol, to intensive care unit, 11–16
- Hawthorne effect, 455–458
- Heart, transplantation of, kidney ischemia during, 1080–1082
- Heart failure
 after aortic surgery, with hiatal hernia, e41–e42
 CABG surgery in, 7–8
 diastolic, 1116–1117
 difficult extubation in, 1067–1068
 left ventricular device implanted for, gastric bypass with, 880–882
 pulmonary hypertension in, 940–944, e24–e26
- Heart rate, in general anesthesia, beta blockers effects on, 414–419
- Heartmate II, aortic valve fusion due to, 1060–1062
- Heartport procedure, e35
- Heartworks echocardiography simulator, 481
- Hematology, advances in, 4–6
- Hemodialysis, atrial flutter during, 535–536
- Hemodilution
 cardioprotective effects of, 251–257
 kidney injury due to, 690
- Hemodynamics
 in Cuirass ventilation, 868–872, 873–877
 optimization of, 764–772, 933–939
 in pheochromocytoma surgery, 526–531
- Hemoglobin, levels of, activated coagulation time results and, 563–568
- Hemophilia A, aortic dissection repair with, 660–663

- Hemorrhage. *See* Bleeding and blood loss
- Hemostasis
 for blood conservation, 124–125
 in cardiopulmonary bypass, 674–675, e68–e70
 fibrin sealants for, e75
 interventions for, thromboelastometry effects on, 227–231
- Heparin
 for congenital heart disease surgery, 581–584
 hyperkalemia induced by, 106–109
 resistance to, nafamostat mesilate for, 239–244
 responsiveness to, activated coagulation time results and, 563–568
 thrombocytopenia induced by, after cardiac surgery, 585–590
- Hernia
 hiatal, aortic surgery effects on, e41–e42
 ommental, through foramen of Morgagni, 1156–1158
- Hiatal hernia, aortic surgery effects on, e41–e42
- Hydromorphone, for thoracotomy pain, 83–89
- Hyperfibrinolysis, in cardiopulmonary bypass, 671
- Hyperglycemia
 in diabetic ketoacidosis, 910–916
 intraoperative, insulin therapy for, 828–834
- Hyperkalemia, heparin-induced, 106–109
- Hypertension
 pulmonary
 airway management in, 940–944
 ketamine for, e24–e26
 systemic
 in aortic aneurysm repair, e5–e6
 in pheochromocytoma surgery, 528
- Hypoactive delirium, postoperative, e23–e24
- Hypoperfusion, occult, outcome markers for, 52–57
- Hypotension, in vasoplegic syndrome, methylene blue for, 878–879
- Hypothermia
 for cardiopulmonary bypass, vs. warm conditions, 945–951
 for deep hypothermic cardiac arrest, 333–339
- Hypoxemia
 in CABG, patent foramen ovale and, e38–e39
 in extracorporeal membrane oxygenation, 907–908
 extracorporeal membrane oxygenation for, beta blockers with, 58–63
- Hypoxia, cerebral, measurement of, 1007–1014
- Impedance cardiography, endotracheal, vs. transpulmonary thermodilution, 217–222
- Implantable cardiac defibrillators, implantation of, 139–140
- Infants
 anomalous left coronary artery in, repair of, 286–290, e70–e72
 ductus arteriosus ligation in, e39–e41
- Infections
 in cardiac surgery, 1094–1100
 of device leads, 139–140
 postoperative, from plasma transfusions, 569–574
- Inferior vena cava, renal cell tumor thrombus in, 1124–1130
- Inflammation
 after Ivor Lewis operation, 857–862
 in cardiopulmonary bypass, prevention of, 952–958
 lung, after one-lung ventilation re-expansion, 427–432
- Information technology, 713, 717–718
- Inotropic agents
 for interventional cardiology, 143
 mortality rate with, 70–77
- Insulin
 for CABG, N-terminal pro-brain natriuretic peptide and, 631–636
 intraoperative, for cardiac surgery, 828–834
 for mortality reduction, 764–772
- Intensive care unit
 handoff protocol for, 11–16
 magic bullets in, 455–458
 transesophageal echocardiography in, miniaturized probe for, 95–97
- Intercostal nerve block
 parasternal, for pediatric patients, 439–442
 for video-assisted thoracoscopic surgery, 315–317
- Interleukin-18, in kidney injury, 343
- Internet resources, 762–763
- Interventional cardiology, 134–147
 anesthetic issues in, 141–144
 aortic coarctation repair, 139
 assist devices, 139–140
 cardiac catheterization, 134–137
 congenital heart disease, 141
 defibrillator implantation, 139–140
 electrophysiology procedures, 140–141
 pacemaker implantation, 139–140
 pulmonary artery stenting, 139
 transcatheter valve replacements, 137–139
- Intra-aortic balloon pump
 for cardiac surgery
 complications of, 604–607
 vs. levosimendan, 596–603
 for cardiogenic shock, 161–165
 for mortality reduction, 764–772
- Intrapleural nerve block, for video-assisted thoracoscopic surgery, 315–317
- Intubation, laryngoscopic techniques for, 845–848
- iPhone, anesthesia apps for, 322–326
- Ischemia, bowel, in aortic thrombosis, e13–e15
- Isoflurane, for CABG, 395–402, 791–798
- Isovelocity surface area measurement, automation of, 507–511
- Ivor Lewis operation, anesthesia comparisons for, 857–862
- Jehovah's Witness patients, blood conservation for, 651–653
- Jugular vein, internal
 cannulation of, 979–981, 982–984, 985–988
 guidewire misplacement through, e17–e18
- Jugular venous pressure, brain injury and, 999–1006
- Ketamine, for pulmonary hypertension, e24–e26
- Ketoacidosis, diabetic, in cardiopulmonary bypass, 910–916
- Kidney
 blood flow measurement of, in pediatric patients, 39–45
 dysfunction or failure of
 after CABG, levosimendan effects on, 591–595
 after cardiopulmonary bypass, 64–69, 1080–1082, e19–e20
 biomarkers for, 340–345
 contrast administration and, 804–812
 fenoldopam effects on, 407–413
 prevention of, 687–697
- Kidney injury molecule 1, 342–343
- Kinesin-like protein 6, genetic polymorphisms of, 1109
- Lactate
 in cardiac surgery, jugular venous pressure and, 999–1006
 as marker for occult hypoperfusion, 52–57
- Landmark-guided internal jugular vein cannulation, 979–981, 982–984, 985–988
- Laryngoscopy, video vs. direct, for endotracheal intubation, 845–848
- Learning Intravenous Resuscitation closed-loop learning system, 933–939
- Left atrial appendage
 inverted, 973–974
 occlusion of, 136
- Left ventricular assist devices

- Left ventricular assist devices (*Continued*)
 aortic valve fusion due to, 1060–1062
 aortic valve insufficiency after, 1063–1066
 cerebral blood flow autoregulation preservation with, 1022–1028
 gastric bypass with, 880–882
- Leriche syndrome, 462–464
- Levobupivacaine, for lung surgery, 863–867
- Levosimendan, for cardiac surgery
 vs. intra-aortic balloon pump, 596–603
 kidney function and, 591–595
 for mortality reduction, 764–772
- Lipoprotein(a), as aortic aneurysm biomarker, 960
- Liver
 amiodarone toxicity to, 729–732
 transplantation of, patent foramen ovale discovery during,
 1069–1073
- Local anesthesia, for transcatheter aortic valve implantation, 733–739
- Low cardiac output syndrome, in cardiopulmonary bypass separation,
 608–616
- LUCAS-2 device, as bridge to aortic valve surgery, e50–e51
- Lung
 injury of, in ductus arteriosus ligation, e39–e41
 perfusion of, mechanical ventilation and, e60
 protection of, 448–454
 resection of, postoperative analgesia for, 78–82
 transplantation of
 cerebral air embolism in, 1077–1079
 kidney ischemia during, 1080–1082
- Lutembacher syndrome, surgery for, 1074–1078
- Lymphoma, right atrial, 172–174
- Magic bullets, in cardiac anesthesia, 455–458
- Magnesium
 for arrhythmias, after CABG, 643–650
 control of, in pheochromocytoma surgery, 526–527
 epidural, for postoperative pain, 1055–1059
 imbalance of, in CABG, volatile anesthetics effects on, 395–402
- Mammary artery, harvesting of, cerebral ischemia in, e62–e63
- Mannitol, kidney function and, 693
- Matrix metalloproteinases
 as aortic aneurysm biomarker, 960
 in CABG, volatile anesthetics effects on, 395–402
- Maze procedures, for atrial fibrillation, 1030–1035
- Mechanical ventilation, 486–506
 for acute respiratory distress syndrome, 471–475
 cardiac tamponade and, 303–304
 complex systems for, 495–497
- Cuirass
 after cardiac surgery, 873–877
 in healthy volunteers, 868–872
 for ductus arteriosus ligation, e39–e41
 high-frequency jet, for pulmonary vein isolation, 433–438
 indications for, 486
 lung injury from, 486–488
 lung re-expansion after, inflammation in, 427–432
 mechanisms of, 488–489
 modes of, 489–497
 noninvasive, 497–498
 after surgery, 917–922
 for mortality reduction, 764–772
- one-lung, One-lung ventilation
 pneumonia due to, 1096
 pneumothorax in, e43–e44
 pulmonary perfusion and, e60
- Mechanical ventilation, 486–506 (*Continued*)
 for respiratory failure, after cardiac surgery, 443–447, 448–454,
 e73–e75
 weaning from, 498
- Mediastinum, drain in, pneumomediastinum due to, 104–105
- Metoprolol, increased mortality due to, 764–772
- Methylene blue, for vasoplegic syndrome, 878–879
- Metoclopramide, unmasking pheochromocytoma, 161–165
- Metoprolol, in general anesthesia, heart rate reduction in, 414–419
- Milrinone, mortality rate with, 70–77
- Minimally invasive cardiac surgery. *See also* Endovascular techniques
 aortic valve repair, 7
 blood conservation in, 5
 mitral valve repair, 6, 512–519
- Minocycline, for spinal cord ischemia prevention, 1034–1038
- Misconduct, 181–185
- MitraClip device, 6, 138
- Mitral valve
 annular nonplanarity of, 186–190
 anterior movement of, during liver transplantation, 274–278
 calcification of, 327–333
 echocardiographic anatomy of, 777–784
 injury of, in aortic valve surgery, 748–750
 proximal isovelocity surface area of, 507–511
 regurgitation of
 in aortic regurgitation, 283–285, 1153–1155
 diastolic, 1153–1155
 ischemic, 756–757
 transesophageal echocardiography for, 994–998
 without regional wall motion abnormality, 753–755
 repair of, 186–190
 circumflex artery injury during, 512–519
 transcatheter, 6
 replacement of, 138, 512–519
 scallops of, 777–784
 supraaortic ridge, 346–348
 tilting-disc, transvalvular pressure gradient across, 966–967
 vortex formation at, in cardiopulmonary bypass, 376–380
- Monitoring, advances in, 712–713
- Mortality
 in acute respiratory distress syndrome, surfactant impact on,
 849–856, e50
 after cardiopulmonary bypass, 64–69
 in aortic aneurysm repair, e5–e6
 in aortic dissection, 1139–1144
 in aortic occlusion, 462–464
 in aortic valve replacement, EuroSCORE for, 617–623
 in CABG, body mass index effects on, 813–817
 in cardiac surgery
 insulin therapy and, 828–834
 prediction with EuroSCORE, 258–264
 in cardiopulmonary bypass
 corticosteroid effects on, 952–958
 during separation, 608–616
 in carotid stenosis, treatment comparisons for, 835–844
 with intra-aortic balloon pump, 604–607
 milrinone effects on, 70–77
 prediction of, transthoracic echocardiography for, 989–993
 reduction of, 455–458, 764–772
 from undiagnosed pheochromocytoma, 161–165
 in vascular surgery, socioeconomic position and, 420–426
- Multimodal analgesia, for video-assisted thoracoscopic surgery, 317
- Mupirocin, preoperative, 1097
- Myocardial ischemia, morphine effects on, 403–406

- Myocardial performance index, during aortic cross-clamping, 204–208
- Myocardial protection
 in cardiopulmonary bypass, 945–951
 erythropoietin in, 251–257
 opioid receptors in, 403–406
- Myopathy, statin-induced, 1109
- Myxoma, atrial, removal of, totally thoracoscopic surgery for, 270–273
- Nafamostat mesilate, for heparin resistance, 239–244
- Nasogastric tube, pulmonary edema from, e37–e38
- Natriuretic peptide, prognostic value of
 for aortic surgery, 637–642
 for cardiac surgery, 624–630, e6
- Near-infrared spectroscopy
 for cerebral blood flow, after left ventricular assist device
 implantation, 1022–1028
 for cerebral ischemia, in superior vena cava obstruction, e27–e28,
 e62–e63
- Nephrectomy, renal cell tumor thrombus during, 1124–1130
- Neuraxial anesthesia
 for cardiopulmonary bypass, heparin administration and, 581–584
 for mortality reduction, 764–772
- Neutrophil gelatinase-associated lipocalin, in kidney injury, 341–342
- NGAL, in kidney injury, 341–342
- Noncardiac surgery, transesophageal echocardiography during,
 362–370
- Nonplanarity angle, mitral valve, 186–190
- Nonsteroidal antiinflammatory drugs, kidney injury due to, 693–694
- Noonan syndrome, pulmonary artery anomalies in, repair of, 280–282
- N-terminal pro-brain natriuretic peptide, after CABG, 631–636
- Obesity, omental hernia in, 1156–1158
- Occult hypoperfusion, outcomes markers for, 52–57
- Off-pump CABG. *See* Coronary artery bypass graft (CABG) surgery,
 off-pump
- Omental hernia, through foramen of Morgagni, 1156–1158
- One-lung ventilation
 lung re-expansion after, inflammation in, 427–432
 retromolar tube placement for, e44–e46
 in tracheobronchopathia osteoplastica, e35
- Opioid receptors, in myocardial ischemia, 403–406
- Outcomes. *See also* Mortality
 of aortic aneurysm repair, 637–642
 of aortic dissection, 1139–1144
 of aortic valve replacement, 617–623, 923–932
 of CABG
 aspirin discontinuation and, e35–e36
 body mass index effects on, 813–817
 of cardiac surgery
 with aspirin discontinuation, 245–250
 B-type natriuretic peptide in, 624–630, e6
 cerebral oximetry and, 1015–1021
 chest tube drainage and, 46–51
 N-terminal pro-brain natriuretic peptide in, 631–636
 prediction with EuroSCORE, 258–264
 of cardiopulmonary bypass, vs. duration, e18
 of carotid stenosis, 835–844
 of chest tube drainage prevention, e68–e70
 of high thoracic epidural analgesia, 1039–1047, 1048–1054
 occult hypoperfusion markers and, 52–57
 perioperative beta-blocker therapy compliance and, 1029–1033
 of steroids in cardiopulmonary bypass, 952–958
 of vascular surgery, socioeconomic position and, 420–426
- Oximetry, cerebral
 accuracy of, 1007–1014
 for outcome prediction, 1015–1021
- Oxygen saturation, as marker for occult hypoperfusion, 52–57
- Oxygen therapy, for mortality reduction, 764–772
- Oxygenation
 in acute respiratory distress syndrome, surfactant impact on,
 849–856, e50
 in Cuirass ventilation, 868–872, 873–877
- Pacing and pacemakers
 after cardiopulmonary bypass, 291–301
 biventricular, optimization of, 209–216
 implantation of, 139–140
- Papillary muscle, adjacent to pulmonary artery catheter, 175–177
- Parasternal intercostal block, for postoperative pain, 439–442
- Paravertebral anesthesia or analgesia
 for lung surgery, 863–867
 for thoracotomy, 78–82, 83–89, 666–668, e28–e30
 for video-assisted thoracoscopic surgery, 90–94, 314–315
- Patent ductus arteriosus, closure of, 136
- Patent foramen ovale
 closure of, 134–135
 color M-mode echocardiography for, e67–e68
 discovery of, during liver transplantation, 1069–1073
 incidental detection of, 721–728
- Pediatric patients. *See also* Congenital heart disease
 acute respiratory distress syndrome in, prone ventilation for,
 471–475
 anomalous left coronary artery in, repair of, 286–290, e70–e72
 atrial septal defect closure in, 537–539
 cardiac surgery for, blood conservation for, 651–653
 cardiopulmonary bypass in
 air embolism in, 468–470
 steroids for, 955–956
 drowning in, extracorporeal membrane oxygenation implantation
 for, 887–889
 inverted left atrial appendage in, 973–974
 pacing for, 299
 parasternal intercostal block for, 439–442
 pulmonary artery anomalies in, repair of, 280–282
 renal blood flow measurement in, 39–45
- Penn classification, for aortic dissection, 1139–1144
- Pentoxifylline, kidney function and, 693
- Percutaneous dilatation tracheostomy, ultrasound guidance for,
 e72–e73
- Percutaneous techniques, for acute coronary syndrome, 7
- Perfusion, blood conservation measures with, 5–6
- Pharmacogenomics
 of beta blockers, 1101–1107
 of statins, 1107–1111
- Pheochromocytoma
 perioperative hemodynamic control in, 526–531
 undiagnosed, cardiogenic shock in, 161–165
- Phtharal product, for disinfection, black denaturalization due to,
 e18–e19
- Plasma transfusions
 decisions for, rotational thromboelastometry for, 1087
 infections related to, 569–574
- Platelet count, activated coagulation time results and, 563–568
- Platelet function, aspirin discontinuation and, e35–e36
- Platelet transfusions, decisions for, rotational thromboelastometry for,
 1087
- Pneumomediastinum, from malpositioned mediastinal drain, 104–105
- Pneumonia, ventilator-associated, 1096
- Pneumothorax
 atrial fibrillation in, e43–e44
 tension, from malpositioned mediastinal drain, 104–105

- Positioning, in pulmonary artery catheterization, arrhythmias in, 391–394
- Postoperative care
 protocol for, 11–16
 transesophageal echocardiography in, 95–97
- Postoperative pain
 epidural magnesium for, 1055–1059
 gabapentin for, e26
 parasternal intercostal block for, 439–442
 paravertebral analgesia for, 863–867
 in thoracotomy, 78–82, 83–89
 in video-assisted thoracoscopic surgery, 90–94, 312–321
- Post-traumatic stress disorder, after cardiac surgery, 265–269
- Potassium, for CABG, N-terminal pro-brain natriuretic peptide and, 631–636
- Prasugrel, perioperative management of, 686
- Premature atrial contractions, in bowel surgery, 751–752
- Probrain natriuretic peptide, vs. echocardiographic results, 197–203
- Procoagulant factors, in cardiopulmonary bypass, 674–675
- Prohemostatic factors, in cardiopulmonary bypass, 674–675
- Prone position
 for ventilation, in infants, 471–475
 for ventricular assist devices, e6–e7
- Propofol, for Ivor Lewis operation, 857–862
- Protease inhibitors, in cardiopulmonary bypass, 674
- Protease-activated receptor inhibitors, perioperative management of, 684
- Protection, yocardial. *See* Myocardial protection
- Prothrombin complex concentrates
 in cardiopulmonary bypass, 676
 decisions for, rotational thromboelastometry for, 1087
- Proximal isovelocity surface area measurement, automation of, 507–511
- Pseudoaneurysm
 of left ventricle, 349–351
 saphenous vein graft, 1148–1149
- Pulmonary artery
 aneurysm of, with associated anomalies, 280–282
 anomalous left coronary artery arising from, e70–e72
 catheterization of
 arrhythmias during, position impact on, 391–394
 kinked catheter in, e61–e62
 papillary muscle adjacent to, 175–177
 left coronary artery arising from, 286–290
 migrated stent in, 1150–1152
 stenting of, 139
 thrombectomy of, kidney ischemia during, 1080–1082
- Pulmonary edema
 in drowning, extracorporeal membrane oxygenation implantation for, 887–889
 from nasogastric tube, e37–e38
- Pulmonary hypertension
 airway management in, 940–944
 ketamine for, e24–e26
- Pulmonary valve
 evaluation of, echocardiography for, 32–38
 replacement of, 138
 stenosis of, totally thoracoscopic surgery for, 270–273
- Pulmonary vein
 anomalous, with atrial septal defect, 975–977
 isolation of, 141, 433–438
- Pulmonary venous diastolic flow, in aortic regurgitation, 283–285
- Pulse, irregular, in bowel surgery, 751–752
- Pulse contour analysis, vs. echocardiography, for cardiac output, 223–226
- Pulse pressure variation, after CABG, fluid responsiveness and, 387–390
- Quality of life, with refractory angina pectoris, 822–828
- RACHS score, early extubation and, 773–775
- Radial artery, cannulation of, ultrasound-guided, e30–e31
- Radiation exposure, in interventional cardiology, 143–144
- Radiography, for omental hernia, 1156–1158
- Randomized controlled trials, for mortality reduction, 455–458
- Remifentanyl, for cardiac surgery, 110–116
- Renal cell tumor thrombus, during nephrectomy, 1124–1130
- Research, highlights of 2011, 3–10
- Respiratory failure
 extracorporeal membrane oxygenation for, beta blockers with, 58–63
 noninvasive ventilation for, 443–447, e73–e75
- Respiratory variation, in electrocardiography, stroke volume and, 381–386
- Resynchronization therapy, optimization of, 209–216
- Rhabdomyolysis, statin-induced, 1109
- Ridge, in left atrium, 346–348
- Risk assessment, for cardiac surgery, EuroSCORE in, 258–264
- Rivaroxaban, 4, 736–742
- Robotic cardiac surgery
 anesthesia for, 270–273
 future of, 718
- Ropivacaine, for parasternal intercostal block, 439–442
- Rotational thromboelastometry (ROTEM), 1083–1093
- Safety, promotion of, 715
- Saphenous vein graft, pseudoaneurysm, 1148–1149
- Scientific misconduct, 181–185
- Sedation
 for extracorporeal membrane oxygenation, 901
 vs. general anesthesia, for interventional cardiology, 141–142
 for transcatheter aortic valve implantation, 733–739
- Sevoflurane
 for CABG, 395–402, 791–798
 for Ivor Lewis operation, 857–862
- Shock, cardiogenic, in pheochromocytoma, 161–165
- Simulation, for echocardiography education, 476–485
- Sinoatrial node, dysfunction of, in right atrial lymphoma, 172–174
- Sinus of Valsalva, aneurysm of, misdiagnosis of, 349–351
- Smart phone, anesthesia apps for, 322–326
- Socioeconomic position, vascular surgery outcome and, 420–426
- Speckle tracking ultrasound
 for left ventricular systolic strain measurement, 17–25
 vs. probrain natriuretic peptide, for preoperative evaluation, 197–203
 for strain measurement, 17–25
- Spectral entropy monitoring, for anesthetic dosage determination, 818–821
- Spinal cord, ischemia of, minocycline for, 1034–1038
- Standardization, 716
- Statins
 for aortic aneurysm, 960–961
 for kidney injury prevention, 688
 pharmacogenomics of, 1107–1111
- Stents
 carotid artery, 166–171
 migrating to pulmonary artery, 1150–1152
- Sternotomy
 for extracorporeal membrane oxygenation implantation, 887–889
 postoperative pain in, parasternal intercostal block for, 439–442
 repeat, for blood loss, 550–556

- Sternum, fracture of, in drug abuser, 532–534
- Steroids in Cardiac Surgery trial, 952–958
- Strain measurement, speckle tracking for, 17–25.26–31
- Stress, cardiomyopathy in, after foramen ovale closure, e52–e54
- Stroke
- aspirin discontinuation effects on, 245–250
 - in carotid stenosis, treatment comparisons for, 835–844
 - in heparin resistance, nafamostat mesilate and, 239–244
- Stroke volume
- measurement methods for, 217–222
 - optimization of, training for, 933–939
 - variation of, with respiration, 381–386
- Subclavian artery, injury of, in central venous catheter insertion, 101–103
- Subclavian vein, cannulation of, halo traction device for, e56–e58
- Subcutaneous emphysema, central venous cannulation with, e46
- Sublingual microcirculation, in cardiopulmonary bypass, 785–790
- Superior vena cava obstruction, cerebral ischemia in, near-infrared spectroscopy for, e27–e28, e62–e63
- Superior vena cava syndrome, in dialysis, 1150–1152
- Surfactant, for acute respiratory distress syndrome, 849–856, e50
- Surgical site infections, 1094–1095
- Systolic function, probrain natriuretic peptide vs. echocardiographic results, 197–203
- Tamponade, cardiac, after cardiac surgery, 302–311
- Tau proteins, in cardiac surgery, jugular venous pressure and, 999–1006
- Teaching. *See* Education
- Technology
- anesthesia apps, 322–326
 - emerging, 1101–1114
 - impact on clinical practice, 711–720
- Tetralogy of Fallot, repair of, totally thoracoscopic surgery for, 270–273
- Thebesian valve, perforated membrane attached to, 1074–1078
- Thermodilution, transpulmonary, vs. endotracheal bioimpedance cardiography, 217–222
- Thoracic epidural anesthesia or analgesia
- high, for cardiac surgery, 1039–1047, 1048–1054
 - long-term, refractory angina pectoris and, 822–828
 - for thoracotomy, 78–82, e28–e30
- Thoracic paravertebral analgesia, for lung surgery, 863–867
- Thoracic surgery
- infectious complications of, 1094–1100
 - noninvasive ventilation after, 919–921
 - postoperative epidural magnesium for, 1055–1059
- Thoracoscopic surgery
- for cardiac disorders, 270–273
 - right ventricle laceration in, 98–100
 - video-assisted
 - pain management after, 312–321
 - paravertebral anesthesia for, 90–94
- Thoracotomy
- paravertebral analgesia for, 863–867
 - paravertebral catheter placement for, 666–668
 - postoperative analgesia for, 78–82, e28–e30
- Thrombectomy, pulmonary artery, kidney ischemia during, 1080–1082
- Thrombin, activation of, in cardiopulmonary bypass, reduction of, 557–562
- Thrombin inhibitors, 4
- Thromboangiitis obliterans, CABG with, e42–e43
- Thrombocytopenia, heparin-induced, after cardiac surgery, 585–590
- Thromboelastometry
- effects on hemostatic interventions, 227–231
 - Thromboelastometry (*Continued*)
 - for fibrinogen concentrate therapy monitoring, 654–659, e54–e56
 - rotational, 1083–1093
- Thrombosis and thrombi
- aortic, bowel ischemia in, e13–e15
 - apixaban for, 742
 - in diabetic ketoacidosis, 914
 - heparin-induced, 585–590
 - intracardiac
 - during extracorporeal membrane oxygenation, 664–665, e12–e13
 - during liver transplantation, 1069–1073
 - in left atrium, 354–355
 - during nephrectomy, 1124–1130
- Ticagrelor, perioperative management of, 686–687
- Toll-like receptor 4, genetic polymorphisms of, 1109–1110
- Topical hypothermia, with deep hypothermic cardiac arrest, 333–339
- Tracheobronchopathia osteoplastica, one-lung ventilation in, e35
- Tracheostomy, percutaneous dilatation, ultrasound guidance for, e72–e73
- Training. *See* Education
- Tranexamic acid
- for blood conservation, 5, 122–123
 - for elderly persons, 232–238
- Transcatheter procedures
- aortic valve implantation (TAVI), 6–7, 136–138, 689–710, 733–739
 - mitral valve repair, 6
 - valve replacement, 138
- Transcutaneous electrical nerve stimulation, for video-assisted thoracoscopic surgery, 317
- Transesophageal echocardiography
- for aortic aneurysm repair, 204–208
 - for aortic dissection, e3–e5
 - for aortic thrombosis, e13–e15
 - for aortic valve monitoring, 1063–1066
 - for aortic valve replacement, 95–97, 688–710
 - for aorto-atrial fistula, e76–e78
 - for atrial clot, e12–e13
 - for atrial septal defect, e79–e80
 - for cardiac output, 223–226
 - for cardiac tamponade, 305–306
 - for cardiac thrombosis, 664–665
 - for coronary sinus obstruction, 1074–1078
 - disinfectant used in, black denaturalization in, e18–e19
 - emergency, 359–361, 362–370
 - for funnel-shaped right coronary ostium, 352–353
 - for heart defects during liver transplantation, 274–278
 - for inverted left atrial appendage, 973–974
 - for kidney ischemia, 1080–1082
 - for left atrial ridge, 346–348
 - for left ventricular pseudoaneurysm, 349–351
 - for lung transplantation, 1077–1079
 - for migrated stent in pulmonary artery, 1150–1152
 - miniaturized probe for, 95–97
 - for mitral leaflet injury, 748–750
 - for mitral valve anatomy, 777–784
 - for mitral valve calcification, 327–333
 - for mitral valve planarity, 186–190
 - for mitral valve regurgitation, 753–755, 994–998, 1153–1155
 - in noncardiac surgery, 356–357
 - for patent foramen ovale, 1069–1073
 - for penetrating chest trauma, e3
 - proximal isovelocity surface area measurement, 507–511
 - for regional wall motion, 371–375
 - for renal blood flow measurement, in pediatric patients, 39–45

- Transesophageal echocardiography (*Continued*)
 for renal cell tumor thrombus, 1124–1130
 for retained fibrin sleeve, 883–886
 for right atrial lymphoma, 172–174
 for segmental wall motion abnormalities, 191–196
 simulation in, 476–485
 stroke volume variations in, 381–386
 three-dimensional, for mitral valve scallop, 777–784
 for tilting-disc mitral valve, 966–967
 vs. transthoracic echocardiography, 17–25, 26–31
 for tricuspid valve regurgitation, 522–524, 525
 for unicuspid aortic valve, 277–279
 for ventricular bullet emboli, 459–461
- Transfusions
 blood conservation for, 4–6, 117–133, e75
 decisions on, 125–126
 fresh frozen plasma, 5, 654–659, e54–e56
 kidney injury due to, 693
 with leukocyte-depleted products, 764–772
 management of, thromboelastometry effects on, 227–231
 optimization of, rotational thromboelastometry in, 1083–1093
 plasma, infections related to, 569–574
 reduction of, 545–549
 risks of, 118–120
 usage of, tranexamic acid impact on, 232–238
 variable practice in, 541–544
- Transplantation
 heart, kidney ischemia during, 1080–1082
 liver
 left ventricular outflow obstruction and mitral valve defect with, 274–278
 patent foramen ovale discovery during, 1069–1073
 lung
 cerebral air embolism in, 1077–1079
 kidney ischemia during, 1080–1082
- Transpulmonary thermodilution, vs. endotracheal bioimpedance cardiography, 217–222
- Transthoracic echocardiography
 for atrial septal defect, e79–e80
 for perioperative mortality prediction, 989–993
 for saphenous vein graft pseudoaneurysm, 1148–1149
 simulation in, 476–485
 vs. transesophageal echocardiography, 17–25, 26–31
- Transvalvular pressure gradient, across tilting-disc mitral valve, 966–967
- Trauma
 chest, in drug abuse, 532–534
 rotational thromboelastometry in, 1083–1093
 transesophageal echocardiography for, e3
- Tricuspid valve
 adjacent to pulmonary artery catheter, 175–177
 evaluation of, echocardiography for, 32–38
 regurgitation of, laminar flow in, 522–524, 525
 replacement of, 138, 878–879
- Ultrasonography
 for central venous catheter placement, 979–981, 982–984, 985–988, e46
 for paravertebral catheter placement, 666–668
 for radial artery cannulation, e30–e31
 for tracheostomy, e72–e73
- Unicuspid aortic valve, echocardiography for, 277–279
- Urinary catheters, infections in, 1095–1096
- Vacuum-assisted venous drainage, for cardiopulmonary bypass, air embolism in, 468–470
- Valvular heart disease. *See also specific valves*
 surgery for
 cerebral oximetry measurement in, 1015–1021
 Cuirass ventilation after, 873–877
 early extubation after, 773–775
 hemostasis interventions in, thromboelastometry effects on, 227–231
 heparin resistance in, 239–244
 heparin-induced thrombocytopenia after, 585–590
 kidney ischemia during, 1080–1082
 occult hypoperfusion markers in, 52–57
 post-traumatic stress disorder after, 265–269
 respiratory failure after, noninvasive ventilation for, 443–447, e73–e75
- Vascular surgery
 atrial thrombi discovery during, 354–355
 general anesthesia for, preoperative beta blockers in, 414–419
 mortality in, socioeconomic position and, 420–426
- Vasoplegic syndrome, methylene blue for, 878–879
- Vasopressin, in pheochromocytoma surgery, 528
- Vasospasm, coronary artery, e78–e79
- Venous reservoir, for cardiopulmonary bypass, 557–562
- Venovenous extracorporeal membrane oxygenation, 893–909
 cannulae and cannulation for, 899–901
 circuit of, 894–899
 complications of, 906–908
 discontinuation of, 908
 physiology of, 893–894
 procedures for, 901–906
 weaning from, 908
- Ventricle(s)
 left
 outflow tract obstruction of, during liver transplantation, 274–278
 pseudoaneurysm of, 349–351
 systolic strain measurement in, 17–25
 right
 bullet emboli in, 459–461
 function of, echocardiography for, 32–38
 laceration of, extracorporeal membrane oxygenation for, 98–100
- Ventricular assist devices, 139. *See also* Left ventricular assist devices
 prone surgical positions for, e6–e7
- Ventricular septal defect
 closure of, 135
 repair of
 early extubation after, 773–775
 totally thoracoscopic surgery for, 270–273
- Vertebral vein, guidewire misplacement into, e17–e18
- Video laryngoscopy, vs. direct laryngoscopy, for endotracheal intubation, 845–848
- Video-assisted thoracoscopic surgery
 epidural magnesium for, 1055–1059
 pain management after, 312–321
 paravertebral anesthesia for, 90–94
- Vimedix echocardiography simulator, 479–481
- Virtual transesophageal electrocardiography program, 482–483
- Volatile anesthetics
 for CABG, 395–402, 791–798
 for mortality reduction, 764–772
- Volume therapy. *See* Fluid therapy
- Vortex formation, inhibition of, in cardiopulmonary bypass, 376–380
- Warm heart surgery, vs. hypothermia, 945–951
- WATCHMAN Left Atrial Appendage Occlusion device, 136
- Weight, CABG mortality and, 813–817
- Western Denmark Heart Registry, 258–264